# US 4,395,400 A · Nonapeptide, a process for its preparation, an agent containing it and its use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,395,400 A
- Document ID: US4395400A
- Status: Granted
- Kind: A
- Application number: 06/268,677
- Filed: 1981-06-01
- Granted: 1983-07-26
- Earliest claimed: 1980-06-03
- Assignees: Hoechst Aktiengesellschaft
- Inventors: Wolfgang Konig; Rolf Geiger; Jurgen K. Sandow
- Web page: https://patentgrep.com/patent/US4395400A

## CPC

- C07K 7/23: Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y10S 930/13: Luteinizing hormone-releasing hormone; related peptides
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

What are disclosed are a nonapeptide of the formula ##STR1## wherein D-Aad (OBu.sup.t) represents D-.alpha.-aminoadipic acid .delta.-tert. butyl ester, methods for making this peptide, pharmaceutical preparations containing this peptide, and methods for its use in increasing fertility or for contraception.

## Claims

### Claim 1

The peptide of the formula ##STR16## in which -D-Aad(OBu.sup.t)- represents D-.alpha.-aminoadipic acid .delta.-tert.-butyl ester.

### Claim 2 (depends on 1)

A pharmaceutical composition for increasing fertility or for inducing contraception, said composition comprising an amount, pharmaceutically effective for the intended use of the preparation, of the peptide of claim 1 dissolved in an aqueous buffer solution as a carrier.

### Claim 3 (depends on 1)

A method for increasing fertility in a patient requiring such treatment which comprises intranasally administering to said patient a low dose of the peptide of claim 1.

### Claim 4 (depends on 1)

A method for inducing contraception in a patient requiring such treatment which comprises nasally administering to said patient a high dose of the peptide of claim 1 on a repeated daily basis.